Deerochanawong Chaicharn, Bajpai Shailendra, Dwipayana I Made Pande, Hussein Zanariah, Mabunay Maria Aileen, Rosales Reynaldo, Tsai Shih-Tzer, Tsang Man Wo
Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand.
, Sanofi, Singapore.
Diabetes Ther. 2017 Dec;8(6):1197-1214. doi: 10.1007/s13300-017-0322-z. Epub 2017 Nov 1.
Various data have demonstrated inadequate glycemic control amongst Asians with type 2 diabetes mellitus (T2DM), possibly on account of suboptimal titration of basal insulin-an issue which needs to be further examined. Here we review the available global and Asia-specific data on titration of basal insulin, with a focus on the use of insulin glargine 100 U/mL (Gla-100). We also discuss clinical evidence on the efficacy and safety of titrating Gla-100, different approaches to titration, including some of the latest technological advancements, and guidance on the titration of basal insulin from international and local Asian guidelines. The authors also provide their recommendations for the initiation and titration of basal insulin for Asian populations. Discussion of the data included in this review and in relation to the authors' clinical experience with treating T2DM in Asian patients is also included. Briefly, clinical studies demonstrate the achievement of adequate glycemic control in adults with T2DM through titration of Gla-100. However, studies investigating approaches to titration, specifically in Asian populations, are lacking and need to be conducted. Given that the management of insulin therapy is a multidisciplinary team effort involving endocrinologists, primary care physicians, nurse educators, and patients, greater resources and education targeted at these groups are needed regarding the optimal titration of basal insulin. Technological advancements in the form of mobile or web-based applications for automated dose adjustment can aid different stakeholders in optimizing the dose of basal insulin, enabling a larger number of patients in Asia to reach their target glycemic goals with improved outcomes.
各种数据表明,2型糖尿病(T2DM)亚洲患者的血糖控制不佳,这可能是由于基础胰岛素滴定未达最佳水平——这一问题需要进一步研究。在此,我们回顾了关于基础胰岛素滴定的全球及亚洲特定数据,重点关注甘精胰岛素100 U/mL(Gla-100)的使用。我们还讨论了滴定Gla-100的疗效和安全性的临床证据、不同的滴定方法,包括一些最新的技术进展,以及国际和亚洲当地指南中关于基础胰岛素滴定的指导。作者还给出了针对亚洲人群起始和滴定基础胰岛素的建议。本文还讨论了本综述中包含的数据,以及作者在治疗亚洲T2DM患者方面的临床经验。简而言之,临床研究表明,通过滴定Gla-100可使成年T2DM患者实现充分的血糖控制。然而,目前缺乏针对滴定方法的研究,特别是在亚洲人群中的研究,因此需要开展此类研究。鉴于胰岛素治疗的管理是一项多学科团队工作,涉及内分泌科医生、初级保健医生、护士教育工作者和患者,需要针对这些群体投入更多资源并开展教育,以实现基础胰岛素的最佳滴定。以移动或基于网络的自动剂量调整应用程序形式出现的技术进步,可帮助不同利益相关者优化基础胰岛素剂量,使更多亚洲患者能够实现其血糖目标并改善治疗效果。